Anti-non-enveloped virus composition and its uses
A PGA-based ion complex with quaternary ammonium cations effectively inactivates non-enveloped viruses, addressing the limitations of existing agents and offering antiviral and food additive formulations.
Patent Information
- Application Number
- JP2026078894
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-19
AI Technical Summary
Existing antiviral agents are ineffective against non-enveloped viruses, which are highly resistant to environmental changes and disinfection, with limited options available beyond chlorine-based disinfectants and alcohol compositions.
A non-enveloped virus-resistant composition comprising poly-γ-glutamic acid (PGA) and a nitrogen-containing compound, forming a poly-γ-glutamic acid ion complex (PGAIC), which includes quaternary ammonium cation compounds, effectively inactivates non-enveloped viruses such as norovirus, rotavirus, poliovirus, parvovirus, and adenovirus.
The PGAIC composition demonstrates concentration-dependent inactivation of non-enveloped viruses, providing a novel antiviral solution for disinfection and food additive applications.
Smart Images

Figure 2026182849000001 
Figure 2026182849000002 
Figure 2026182849000003
Abstract
Description
[Technical Field]
[0001] This invention relates to an anti-non-enveloped virus composition and its uses. [Background technology]
[0002] Unlike enveloped viruses, non-enveloped viruses are known to be highly resistant to environmental changes and to disinfection and temperature fluctuations. For example, surfactants such as quaternary ammonium salts have an inactivating effect on enveloped viruses, but they do not have an inactivating effect on non-enveloped viruses. To date, there have been only a few reports of antiviral agents for non-enveloped viruses, such as chlorine-based disinfectants like sodium hypochlorite and hydrogen peroxide (see Patent Document 1), or compositions of lower alcohols mixed with specific alkaline substances and specific cationic surfactants (see Patent Document 2). [Prior art documents] [Patent Documents]
[0003] [Patent Document 1] Japanese Patent Publication No. 2010-285387 [Patent Document 2] Japanese Patent Publication No. 2008-189645 [Overview of the Initiative] [Problems that the invention aims to solve]
[0004] The present invention aims to provide novel anti-non-enveloped virus compositions, anti-non-enveloped virus agents, disinfectants, and food additive formulations. [Means for solving the problem]
[0005] One embodiment of the present invention is a non-enveloped virus-resistant composition comprising poly-γ-glutamic acid (PGA) and a nitrogen-containing compound. The PGA and the nitrogen-containing compound may form a poly-γ-glutamic acid ion complex (PGAIC). The nitrogen-containing compound may be an ammonium cation compound, or a quaternary ammonium cation compound. The quaternary ammonium cation compound may be a compound represented by the following formula (I) and formula (II).
[0006]
Chemical formula
[0007] (In the formula, R 1 is selected from H and C 1-2 alkyl group, R 2 and R 3 are each independently selected from C 1-15 alkyl group, R 4 and R 5 are each independently selected from C 1-20 alkyl group.) The quaternary ammonium cation compound may be a hexadecylpyridinium cation (HDP + ) or a hexadecyltrimethylammonium cation (HDA + ). Further, the quaternary ammonium cation compound may be a methyltrioctylammonium cation (TOA + ) or a dimethyldioctadecylammonium cation (DSA + ). Further, the non-enveloped virus-resistant composition may be an antiviral composition against norovirus, rotavirus, poliovirus, parvovirus, enterovirus or adenovirus.
[0008] Another embodiment of the present invention is a non-enveloped virus-resistant agent comprising any one of the non-enveloped virus-resistant compositions described above. The non-enveloped virus-resistant agent may be a liquid preparation, a spray, a liniment, a coating agent, an additive, a filler, or a filler.
[0009] A further embodiment of the present invention is a disinfectant comprising any of the above-described non-enveloped virus antiviral compositions. The disinfectant may be a liquid preparation, a spray, a coating agent, a coating composition, an additive, a filler, or a filler material.
[0010] A further embodiment of the present invention is a food additive formulation comprising any of the above-described non-enveloped virus antiviral compositions. The food additive formulation may be a liquid preparation, a spray, a coating agent, a coating composition, an additive, a filler, or a filler material.
Effects of the Invention
[0011] According to the present invention, it has become possible to provide a novel non-enveloped virus antiviral composition, antiviral agent, disinfectant, and food additive formulation.
Modes for Carrying Out the Invention
[0012] The objects, features, advantages, and ideas of the present invention will be apparent to those skilled in the art from the descriptions in the present specification, and those skilled in the art can easily reproduce the present invention from the descriptions herein. The embodiments of the invention and specific examples and the like described below show preferred embodiments of the present invention, are presented for illustration or explanation, and are not intended to limit the present invention thereto. It will be apparent to those skilled in the art that various alterations and modifications can be made based on the descriptions within the intent and scope of the present invention disclosed herein.
[0013] One embodiment of the present invention is a non-enveloped virus antiviral composition comprising poly-γ-glutamic acid (PGA) and a nitrogen-containing compound.
[0014] The non-enveloped virus antiviral composition refers to an antiviral composition against non-enveloped viruses. Herein, the type of non-enveloped virus is not particularly limited, and may be norovirus, rotavirus, poliovirus, parvovirus, enterovirus, or adenovirus.
[0015] In an anti-non-enveloped virus composition, PGA and a nitrogen-containing compound may constitute a poly-γ-glutamate ion complex (PGAIC). Here, PGAIC is an ion complex formed by the hydrophobic bonding of PGA and a nitrogen-containing compound. The nitrogen-containing compound is N + The salt is not particularly limited as long as it has N + The salt having is preferably an ammonium cation compound, more preferably a quaternary ammonium cation compound, and even more preferably selected from quaternary ammonium cation compounds of the following formulas (I) and (II), cationic dye compounds of the following formulas, dequalinium cations, and N,N'-hexamethylenebis (4-carbamoyl-1-decylpyridinium).
[0016] [ka]
[0017] (In the formula, R 1 H and C 1-2 Selected from alkyl groups (i.e., hydrogen, methyl, or ethyl), but preferably methyl, R 2 and R 3 C is independent 1-15 Selected from alkyl groups, C 1-12 Alkyl alkyl group, C 1-9 Alkyl alkyl group, C 1-6 Alkyl alkyl group, C 1-3 It may be selected from alkyl groups, R 4 and R 5 C is independent 1-20 Selected from alkyl groups, C 1-16 Alkyl alkyl group, C 1-12 Alkyl alkyl group, C 1-8 Alkyl alkyl group, C 1-4 (An alkyl group may be selected.)
[0018] [ka]
[0019] [ka]
[0020] [ka]
[0021] The method for converting PGA to PGAIC is not particularly limited, and known methods can be used. For example, PGAIC can be produced by mixing PGA with a nitrogen-containing compound in a solvent. The solvent is not particularly limited and may be water or aqueous solvents, as well as alcohols such as methanol and ethanol, ethers such as THF, and water-soluble organic solvents such as amides such as dimethylformamide and dimethylacetamide, but water is preferred. Since PGAIC is insoluble in water, after mixing PGA with the nitrogen-containing compound, PGAIC can be isolated by filtration or centrifugation. The concentration of PGA to be mixed is not particularly limited, but may be 0.5 w / v% or more, or 10 w / v% or less. The concentration of the nitrogen-containing compound is also not particularly limited, but may be 1.0 w / v% or more, or 10 w / v% or less.
[0022] PGA is a biopolyamide formed by the polymerization of the natural amino acid glutamic acid at its respective α-amino and γ-carboxyl groups, and is known for its stereochemical diversity. As polymers, homopolymers of L-glutamic acid, homopolymers of D-glutamic acid, and copolymers containing L-glutamic acid and D-glutamic acid have been disclosed and are known, and any of them may be used.
[0023] As PGA, salts in which all or some of the carboxyl groups are ionized may be used, for example, alkali metal salts such as sodium salts and potassium salts, and alkaline earth metal salts such as calcium salts and magnesium salts.
[0024] There are no particular limitations on the shape or molecular weight of PGA, but it is preferable that the average molecular weight be 10kD or more, more preferably 30kD or more, even more preferably 90kD or more, preferably 1000kD or less, more preferably 300kD or less, and even more preferably 100kD or less.
[0025] PGA may be obtained using commercially available products, chemically synthesized, or isolated from organisms that produce it. In the case of chemical synthesis, polymerization under general conditions yields poly-α-glutamic acid. Examples of organisms that produce PGA include Bacillus subtilis and Bacillus megaterium, as well as Bacillus anthracis, Bacillus halodurans, Natrialba aegyptiaca, and Hydra, from which PGA may be isolated.
[0026] The antiviral composition described above can be used as an antiviral agent, disinfectant, or food additive preparation. While the dosage form is not particularly limited, it is preferable that it be a liquid, spray, coating agent, additive, filler, or additive that can be mixed with resins or fibers, depending on its application in home appliances, kitchen facilities, kitchen supplies, bathroom facilities, bathroom supplies, office equipment, office supplies, industrial equipment, industrial supplies, telecommunications equipment, accessories, building materials, housing equipment, toilet facilities, toilet supplies, daily necessities, printing supplies, medical supplies, nursing care supplies, healthcare supplies, pet supplies, etc. For example, viruses can be inactivated on or inside a substance by immersing the substance from which the virus is to be removed (e.g., food) in the liquid, spraying the surface of the substance with a spray agent, applying a coating agent, coating the surface of the substance with a coating agent, bringing the substance into contact with fibers or films to which the liquid has been applied, or by mixing it with fibers, resins, paints, etc., as an additive. For example, when mixing PGAIC with acrylic urethane paint, it is preferable to add 0.5% by mass or more of PGAIC, more preferably 1.0% by mass or more, and even more preferably 5.0% by mass or more. [Examples]
[0027] [Example 1] In this study, the anti-norovirus inactivation activity of PGA / HDP (hexadecylpyridinium) complex (ion complex) and PGA / HDA (hexadecyltrimethylammonium) complex were evaluated as PGAICs. <Method> Using PGA powder, HDP powder, and HDA powder, 0.39 molar aqueous solutions of PGA, HDP, and HDA were prepared. Note that PGAIC forms an ion complex with a ratio of 1 mole of countercation compound to 1 mole of α-carboxyl groups of glutamic acid or glutamate salts constituting PGA. Therefore, in the calculation of the required PGA concentration for PGAIC synthesis, glutamic acid or glutamate salts constituting PGA were treated as 1 unit. Specifically, the following formula 1 was used for the molar calculation of PGA.
[0028]
number
[0029] After freeze-drying, the obtained PGA / HDP was dissolved in anhydrous ethanol to prepare PGA / HDP solutions with concentrations of 0.1%, 1%, and 10%, respectively. PGA / HDA was also dissolved in anhydrous ethanol in the same manner as the PGA / HDP solutions to prepare a 10% PGA / HDA solution. A polyethylene terephthalate (PET) plate (5 cm square) was fixed to the rotating disc of a spin coater, and when the rotation speed reached 1000 rpm, 0.5 mL of each solution was dropped over 5 seconds, and after rotating for another 15 seconds, a test plate (hereinafter referred to as the processed plate) with a PGAIC film formed on its surface was obtained by natural drying at 25°C for 1 hour.
[0030] From the change in dry weight after coating, 1m 2 The coating weight per unit was calculated, and the results shown in Table 1 were obtained.
[0031] [Table 1]
[0032] For the anti-non-enveloped virus test, feline calicivirus (F-9 virus; ATCC VR-782) was used as the standard non-enveloped virus, with a ratio of 1-5 × 10⁻¹⁶. 7 Feline calicivirus at pfu / mL was used as the standard virus solution. Feline calicivirus is widely known as a surrogate virus for norovirus, and the results obtained from infection tests using feline calicivirus are applicable to norovirus. The anti-non-enveloped virus test was conducted in accordance with the International Organization for Standardization (ISO) standard (ISO21702). First, 0.4 mL of the standard virus solution was dropped onto the test plate, then a film was placed over it and it was covered and incubated at room temperature under light irradiation for 24 hours. As a control group for this test, an unprocessed 5 cm square plastic test plate (hereinafter referred to as the unprocessed plate) was used and conducted in parallel with the test using the processed plate.
[0033] The plaque method was used to evaluate the viral inactivation effect in this study. Viruses were recovered by washing the processed and unprocessed plates with SCDLP medium (10 mL), and the recovered virus solution was prepared by stepwise 10-fold dilution using maintenance medium (0.95% Eagle Miniature Medium; 0.006% Kanamycin Sulfate). Next, the recovered virus solution (0.1 mL) was seeded onto a 96-well plate cultured with feline epithelial kidney cells (CRFK cells; ATCC CCL-94) and incubated at 37°C for 1 day under 5% CO2 conditions. After that, the cells were fixed with glutaraldehyde solution, stained with methylene blue, and the number of plaques was measured. The inactivation rate was calculated according to the following formula 2. The results are shown in Table 2.
[0034]
number
[0035] [Table 2]
[0036] As shown in Table 2, the control group (untreated board) showed a virus inactivation rate of 0, while PGA / HDP showed a concentration-dependent inactivation effect on norovirus. PGA / HDA similarly exhibited an inactivation effect on norovirus.
[0037] Thus, PGAIC possesses excellent antiviral activity against non-enveloped viruses. [Example 2] In this study, we evaluated not only the anti-norovirus inactivation ability of PGA / HDP (hexadecylpyridinium) complex (ion complex) and PGA / HDA (hexadecyltrimethylammonium) complex as PGAICs, but also the anti-norovirus inactivation ability of PGA / TOA (methyltrioctylammonium) complex and PGA / DSA (dimethyldioctadecylammonium) complex. <Method> The synthesis methods for each composite were the same as in Example 1, however, for the PGA / TOA composite and the PGA / DSA composite, TOA dispersion and DSA dispersion were prepared using TOA powder and DSA powder, respectively, and PGA / TOA and PGA / DSA were synthesized. In this example, PGA / HDP, PGA / HDA, PGA / TOA, and PGA / DSA obtained after freeze-drying were dissolved in anhydrous ethanol to prepare PGA / HDP, PGA / HDA, PGA / TOA, and PGA / DSA solutions with concentrations of 0.3%, 0.5%, and 1.0%, respectively. Test plates (hereinafter referred to as "processed plates") were obtained by dropping each solution onto polyethylene terephthalate (PET) plates (5 cm square) and air-drying at 25°C for 1 hour to form a PGAIC film on the surface. A test plate that was not treated with PGAIC (hereinafter referred to as "unprocessed plate") was used as a control group in this test. In order to compare the amount of quaternary ammonium in the coated PGAIC in a uniform molar amount, the amount of each PGAIC solution dropped was as shown in Table 3. [Table 3] For the anti-non-enveloped virus test, a norovirus particle measurement kit (manufactured by Protex Co., Ltd.) was used, which contained norovirus particles from which the genetic material, RNA, had been removed. The norovirus particles attached to the kit were suspended in 2 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) containing 2 mg / mL BSA (bovine serum albumin) (hereinafter referred to as the virus suspension buffer), and measured at 1.8 × 10⁻⁶. 8 A standard virus suspension was prepared at a concentration of cells / mL. First, 0.3 mL of standard virus suspension was dropped onto both the processed and unprocessed plates, then a film was placed over them to cover them, and the plates were incubated at room temperature under light irradiation for 24 hours. ELISA detection kit (Protex Co., Ltd.) was used to evaluate the virus inactivation effect in this study. Viruses were recovered by washing the incubated treated and untreated plates with virus suspension buffer (0.3 mL). The recovered virus solution (0.1 mL) was added to a 96-well plate coated with an immunoassay targeting norovirus capsid as the antigen, and incubated at 25°C for 1 hour. The recovered virus solution was then removed, and the plate wells were washed five times with washing solution (0.3 mL). Next, recognition antibody solution (0.1 mL) was added to the plate wells and incubated at 25°C for 1 hour. The recognition antibody solution was then removed, and the plate wells were washed five times with washing solution (0.3 mL). After washing, chromogenic solution (0.1 mL) was added, and the mixture was incubated in the dark at 25°C for 30 minutes. The reaction was then completed by adding stop solution (0.1 mL). The absorbance of the solution at 450 nm was measured after the reaction was complete. Furthermore, a calibration curve was created using a norovirus suspension of known concentration, and regression equation 3 was obtained. [Formula 3] Logarithm of virus particle concentration (particles / mL) = 0.834 × (logarithm of absorbance at 450 nm) - 6.70 [Table 4] As shown in Table 4, the control group (untreated board) showed a virus inactivation rate of 0, while PGA / HDP, PGA / HDA, PGA / TOA, and PGA / DSA showed a concentration-dependent inactivation effect on norovirus. Thus, PGAIC possesses excellent antiviral activity against non-enveloped viruses.
Claims
1. An anti-non-enveloped virus composition containing poly-γ-glutamic acid (PGA) and nitrogen-containing compounds.
2. The anti-non-enveloped virus composition according to claim 1, wherein the PGA and the nitrogen-containing compound constitute a polyγ-glutamate ion complex (PGAIC).
3. The anti-non-enveloped virus composition according to claim 1 or 2, wherein the nitrogen-containing compound is an ammonium cation compound.
4. The anti-non-enveloped virus composition according to claim 3, wherein the ammonium cation compound is a quaternary ammonium cation compound.
5. The anti-non-enveloped virus composition according to claim 4, wherein the quaternary ammonium cation compound is a compound represented by the following formulas (I) and (II). 【Chemistry 1】 (In the formula, R 1 H and C 1-2 Selected from alkyl groups, R 2 and R 3 C is independent 1-15 Selected from alkyl groups, R 4 and R 5 C is independent 1-20 (Selected from alkyl groups.)
6. The quaternary ammonium cation compound is a hexadecylpyridinium cation (HDP + ) or a hexadecyltrimethylammonium cation (HDA + ), the non-enveloped virus-resistant composition according to claim 5.
7. The quaternary ammonium cation compound is a methyltrioctylammonium cation (TOA + ) or dimethyldioctadecylammonium cation (DSA + The anti-non-enveloped virus composition according to claim 5, which is the same as the one described in claim 5.
8. An anti-non-enveloped virus composition according to any one of claims 1 to 7, which is an antiviral composition against norovirus, rotavirus, poliovirus, parvovirus, enterovirus, or adenovirus.
9. An anti-non-enveloped virus agent comprising the anti-non-enveloped virus composition according to any one of claims 1 to 8.
10. The anti-non-enveloped virus agent according to claim 9, which is a liquid, spray, coating, additive, filler, or other liquid.
11. A disinfectant for non-enveloped viruses, A disinfectant comprising the anti-non-enveloped virus composition according to any one of claims 1 to 8.
12. The disinfectant according to claim 11, which is a liquid, spray, coating agent, additive, filler, or filler.
13. A food additive formulation for non-enveloped viruses, A food additive formulation comprising the anti-non-enveloped virus composition according to any one of claims 1 to 8.
14. A food additive formulation according to claim 13, which is a liquid, spray, coating, additive, filler, or other liquid.
Citation Information
Patent Citations
Composition effective for inactivation of hydrophilic virus
JP2008189645A
Norovirus deactivator
JP2010285387A
